NCT07579650 Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesia in Mastectomy
| NCT ID | NCT07579650 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-05-16 |
| Primary Completion | 2026-06-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-05-16 with a primary completion date of 2026-06-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effect of serratus posterior superior intercostal plane (SPSIP) block on postoperative pain, opioid consumption, and analgesic requirements in patients undergoing mastectomy and axillary lymph node dissection
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18-65 years * ASA physical status I-III * Scheduled for elective unilateral mastectomy with axillary lymph node dissection under general anesthesia * Able to understand and use the Numeric Rating Scale (NRS) for pain assessment * Provided written informed consent Exclusion Criteria: * Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine) * Coagulopathy, thrombocytopenia (\<100,000/mm³), or ongoing anticoagulant/antiplatelet therapy that cannot be discontinued * Infection or skin lesion at the injection site * Planned bilateral surgery or additional major surgical procedures * Chronic pain conditions or regular use of opioids, gabapentinoids, or centrally acting analgesics * Neurological or psychiatric conditions interfering with pain assessment * History of previous major thoracic or chest wall surgery on the same side * Pregnancy or breastfeeding * Refusal to participate or inability to provide informed consent
Contact & Investigator
Fatma Acil, M.D.
PRINCIPAL INVESTIGATOR
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Frequently Asked Questions
Who can join the NCT07579650 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07579650 currently recruiting?
Yes, NCT07579650 is actively recruiting participants. Contact the research team at acilfatma@gmail.com for enrollment information.
Where is the NCT07579650 trial being conducted?
This trial is being conducted at Diyarbakır, Turkey (Türkiye).
Who is sponsoring the NCT07579650 clinical trial?
NCT07579650 is sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. The principal investigator is Fatma Acil, M.D. at Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.